Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
In our December issue: articles on osteoarthritis therapies, IgG4-related disease, immune-mediated necrotizing myopathy and antinuclear antibody testing.
Image of a bone tissue engineering scaffold implanted in a femur defect model. Image supplied by Betül Aldemir Dikici, University of Sheffield. Cover design: Susanne Harris.
To gauge the relative efficacy of treatments, authors of review articles and commentary might attempt to compare results across clinical trials, but failure to recognize inherent differences across studies or apply proper statistical principles could yield flawed conclusions. Several approaches can mitigate the risks in these cross-trial comparisons.
Gender disparities persist in many aspects of working life for women in academic rheumatology. To move forward, we must find ways to address the gender gap in rheumatology with the goal of creating a workforce as diverse as the patient population it serves.
Cardiac toxicity can be induced by hydroxychloroquine, especially when used in combination with azithromycin. Interest in hydroxychloroquine and azithromycin as potential therapies for COVID-19 has renewed concerns about the possible cardiovascular risk these drugs present to patients with rheumatoid arthritis.
In this Review, the authors describe the pathophysiological targets and clinical effects of new drugs currently being investigated for the treatment of osteoarthritis.
The association of immune-mediated necrotizing myopathy (IMNM) with myositis-specific autoantibodies has led to the classification of three subclasses of IMNM and provided insight into the pathogenesis of, and treatment options for, these inflammatory myopathies.
Over the past few years, considerable advances have been made in understanding the pathogenesis of IgG4-related disease. Our increased knowledge of the important roles of B cells and T cells is now starting to make its way into the clinic.
Antinuclear antibodies (ANAs) are valuable biomarkers for various autoimmune rheumatic diseases and can be detected using various assays. This Review discusses the advantages and disadvantages of different ANA assays, to help in the understanding and interpretation of ANA test results.